![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Jiangxi Synergy Pharmaceutical Co., Ltd. Fengxin Cn, based in China, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their significant offerings is Rivaroxaban, supported by a 'Valid' Certificate of Suitability (CEP) with the number CEP 2021-047 - Rev 01
This Chemical Type CEP, issued on September 28, 2023, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 2932 associated with this CEP further emphasizes